Recommendations for Hepatitis B Immunoglobulin and
Antiviral Prophylaxis Against Hepatitis B Recurrence After
Liver Transplantation

The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. European Association for the Study of the Liver (EASL). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. [CrossRef]
2. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026. [CrossRef]
3. Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33(9):e13514. [CrossRef]
4. Orfanidou A, Papatheodoridis GV, Cholongitas E. Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: current concepts. Liver Int. 2021;41(7):1448-1461. [CrossRef]
5. Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol. 2003;77(16):8882-8892. [CrossRef]
6. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32(6):1189-1195. [CrossRef]
7. United States Preventive Services Task Force. Grade Definitions. Available at: https ://ww w.usp reven tives ervic estas kforc e.org /apps / grad edef. jsp#a fter2 012.
8. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease: viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol. 1992;140(6):1295-1308.
9. Mcgory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61(9):1358- 1364. [CrossRef]
10. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11(4):402-409. [CrossRef]
11. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842-1847. [CrossRef]
12. Verna EC. Updated hepatitis B Guidance: implications for liver transplant patients. Liver Transpl. 2018;24(4):465-469. [CrossRef]
13. Chauhan R, Lingala S, Gadiparthi C, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management. World J Hepatol. 2018;10(3):352-370. [CrossRef]
14. Kiyici M, Yilmaz M, Akyildiz M, et al. Association Between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc. 2008;40(5):1511-1517. [CrossRef]
15. Idilman R, Akyildiz M, Keskin O, et al. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. Clin Transplant. 2016;30(10):1216-1221. [CrossRef]
16. Han S, Na GH, Kim DG. A 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxis. Drug Des Devel Ther. 2017;11:2099-2107. [CrossRef]
17. Maiwall R, Kumar M. Prevention and treatment of recurrent hepatitis B after liver transplantation. J Clin Transl Hepatol. 2016;4(1):54- 65. [CrossRef]
18. Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol. 2018;9(1):79-84. [CrossRef]
19. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132(3):931-937. [CrossRef]
20. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther. 2004;9(6):921-927.
21. Vatansever S, Farajov R, Yılmaz HC, Zeytunlu M, Kılıç M. The efficiency of low-dose hepatitis B immunoglobulin plus neucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence. Turk J Med Sci. 2019;49(4):1019-1024. [CrossRef]
22. Shen S, Jiang L, Xiao GQ, et al. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol. 2015;21(2):584-592. [CrossRef]
23. Akcam AT, Ulku A, Rencuzogullari A, et al. Antiviral combination therapy with low-dose hepatitis B immunoglobulin for the prevention of hepatitis B virus recurrence in liver transplant recipients: a singlecenter experience. Transplant Proc. 2015;47(5):1445-1449. [CrossRef]
24. Karasu Z, Akyildiz M, Kilic M, et al. Living donor liver transplantation for hepatitis B cirrhosis. J Gastroenterol Hepatol. 2007;22(12):2124-2129. [CrossRef]
25. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13(2):353-362. [CrossRef]
26. Degertekin B, Han SHB, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10(8):1823-1833. [CrossRef]
27. Ferrari C. HBV and the immune response. Liver Int. 2015;35(suppl 1):121-128. [CrossRef]
28. Dehghani SM, Taghavi SAR, Geramizadeh B, et al. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. Hepat Mon. 2013;13(1):e6609. [CrossRef]
29. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. India: Springer; 2016.
30. Costanzo GG Di, Lanza AG, Picciotto FP, et al. Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study. Am J Transplant. 2013;13(2):348-352. [CrossRef]
31. Choudhary NS, Saraf N, Saigal S, et al. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis? Transpl Infect Dis. 2015;17(3):329-333. [CrossRef]
32. Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res. 2013;43(1):67-71. [CrossRef]
33. Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl. 2008;14(4):435-442. [CrossRef]
34. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17(10):1176-1190. [CrossRef]
35. Marzano A, Marengo A, Andreone P, et al. Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. Minerva Med. 2010;101(6):373-383.
36. Yahyazadeh A, Beckebaum S, Cicinnati V, et al. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int. 2011;24(5):441-450. [CrossRef]
37. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Costeffective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003;17(3):254-258. [CrossRef]
38. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14(suppl 2):S15-S22. [CrossRef]
39. Hwang S, Lee SG, Ahn CS, et al. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl. 2008;14(6):770-778. [CrossRef]
40. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl. 2012;18(5):514-523. [CrossRef]
41. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22(4):387-394. [CrossRef]
42. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6(6):696-700. [CrossRef]
43. Roche B, Samuel D. Liver transplantation for hepatitis B virusrelated liver disease: indications, prevention of recurrence and results. J Hepatol. 2003;39(suppl 1):S181-S189. [CrossRef]
44. Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol. 2013;19(48):9189-9197. [CrossRef]
45. Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology. 2017;66(4):1036-1044. [CrossRef]
46. Lee WC, Chou HS, Wu TH, et al. Low-dose anti-hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation. Transpl Infect Dis. 2019;21(6):e13190. [CrossRef]
47. Cholongitas E, Vasiliadis T, Antoniadis N, et al. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis. 2012;14(5):479-487. [CrossRef]
48. Fernández I, Loinaz C, Hernández O, et al. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis. 2015;17(5):695-701. [CrossRef]
49. Rodríguez M, Buti M, Esteban R, et al. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol. 2020;43(9):559-587. [CrossRef]
50. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. [CrossRef]
51. Yoshizawa A, Yamashiki N, Ueda Y, et al. Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res. 2016;46(6):541-551. [CrossRef]
52. Ikeda A, Takaki A, Yasunaka T, et al. Predictive factors for sucsessful vaccination against hepatitis B surface antigen in patient who have undergone orthotopic liver transplantation. Acta Med Okayama. 2019;73(1):41-50. [CrossRef]
53. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7(1):31-40. [CrossRef]
54. Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32(3):245-255. [CrossRef]
55. Burra P, Burroughs A, Graziadei I, European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64(2):433-485. [CrossRef]
56. Cholongitas E, Goulis I, Antoniadis N, et al. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation. Transpl Infect Dis. 2016;18(5):667-673. [CrossRef]
57. Adil B, Fatih O, Volkan I, et al. Hepatitis B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus. Transplant Proc. 2016;48(6):2119-2123. [CrossRef]
58. Serin A, Tokat Y. Recurrence of hepatitis D virus in liver transplant recipients with hepatitis B and D virus-related chronic liver disease. Transplant Proc. 2019;51(7):2457-2460. [CrossRef]
59. Hammami MB, Kohli R, Woreta T, et al. Hepatitis B virus/hepatitis D virus–coinfected liver transplant candidate receiving hepatitis B virus-deoxyribonucleic acid–positive allograft and treated with highdose hepatitis B immune globulin. ACG Case Rep J. 2021;8(5):e00582. [CrossRef]
60. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10(5):1268-1275. [CrossRef]
61. Congly SE, Doucette KE, Coffin CS. Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation. World J Gastroenterol. 2014;20(2):414-424. [CrossRef]

APA	akarsu m, Onem S, TURAN I, ADALI G, Akdogan M, AKYILDIZ M, Aladag M, balaban h, Danis N, DAYANGAC M, gençdal g, Gokcan H, Sertesen E, Gurakar M, Harputluoglu M, Kabaçam G, Karademir S, KIYICI M, Idilman R, karasu z (2021). Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. , 712 - 719. 10.5152/tjg.2021.21608
Chicago	akarsu mesut,Onem Soner,TURAN ILKER,ADALI GUPSE,Akdogan Meral,AKYILDIZ MURAT,Aladag Murat,balaban hatice yasemin,Danis Nilay,DAYANGAC MURAT,gençdal genco,Gokcan Hale,Sertesen Elif,Gurakar Merve,Harputluoglu Murat,Kabaçam Gökhan,Karademir Sedat,KIYICI Murat,Idilman Ramazan,karasu zeki Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. (2021): 712 - 719. 10.5152/tjg.2021.21608
MLA	akarsu mesut,Onem Soner,TURAN ILKER,ADALI GUPSE,Akdogan Meral,AKYILDIZ MURAT,Aladag Murat,balaban hatice yasemin,Danis Nilay,DAYANGAC MURAT,gençdal genco,Gokcan Hale,Sertesen Elif,Gurakar Merve,Harputluoglu Murat,Kabaçam Gökhan,Karademir Sedat,KIYICI Murat,Idilman Ramazan,karasu zeki Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. , 2021, ss.712 - 719. 10.5152/tjg.2021.21608
AMA	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. . 2021; 712 - 719. 10.5152/tjg.2021.21608
Vancouver	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. . 2021; 712 - 719. 10.5152/tjg.2021.21608
IEEE	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z "Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation." , ss.712 - 719, 2021. 10.5152/tjg.2021.21608
ISNAD	akarsu, mesut vd. "Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation". (2021), 712-719. https://doi.org/10.5152/tjg.2021.21608

APA	akarsu m, Onem S, TURAN I, ADALI G, Akdogan M, AKYILDIZ M, Aladag M, balaban h, Danis N, DAYANGAC M, gençdal g, Gokcan H, Sertesen E, Gurakar M, Harputluoglu M, Kabaçam G, Karademir S, KIYICI M, Idilman R, karasu z (2021). Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology, 32(9), 712 - 719. 10.5152/tjg.2021.21608
Chicago	akarsu mesut,Onem Soner,TURAN ILKER,ADALI GUPSE,Akdogan Meral,AKYILDIZ MURAT,Aladag Murat,balaban hatice yasemin,Danis Nilay,DAYANGAC MURAT,gençdal genco,Gokcan Hale,Sertesen Elif,Gurakar Merve,Harputluoglu Murat,Kabaçam Gökhan,Karademir Sedat,KIYICI Murat,Idilman Ramazan,karasu zeki Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology 32, no.9 (2021): 712 - 719. 10.5152/tjg.2021.21608
MLA	akarsu mesut,Onem Soner,TURAN ILKER,ADALI GUPSE,Akdogan Meral,AKYILDIZ MURAT,Aladag Murat,balaban hatice yasemin,Danis Nilay,DAYANGAC MURAT,gençdal genco,Gokcan Hale,Sertesen Elif,Gurakar Merve,Harputluoglu Murat,Kabaçam Gökhan,Karademir Sedat,KIYICI Murat,Idilman Ramazan,karasu zeki Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology, vol.32, no.9, 2021, ss.712 - 719. 10.5152/tjg.2021.21608
AMA	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology. 2021; 32(9): 712 - 719. 10.5152/tjg.2021.21608
Vancouver	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turkish Journal of Gastroenterology. 2021; 32(9): 712 - 719. 10.5152/tjg.2021.21608
IEEE	akarsu m,Onem S,TURAN I,ADALI G,Akdogan M,AKYILDIZ M,Aladag M,balaban h,Danis N,DAYANGAC M,gençdal g,Gokcan H,Sertesen E,Gurakar M,Harputluoglu M,Kabaçam G,Karademir S,KIYICI M,Idilman R,karasu z "Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation." Turkish Journal of Gastroenterology, 32, ss.712 - 719, 2021. 10.5152/tjg.2021.21608
ISNAD	akarsu, mesut vd. "Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation". Turkish Journal of Gastroenterology 32/9 (2021), 712-719. https://doi.org/10.5152/tjg.2021.21608